Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line.
Cryptosporidium parvum is a protozoan parasite that causes severe enteritis in patients with AIDS for which there is no effective therapy. Paromomycin is a nonabsorbable aminoglycoside that is effective in the treatment of other intestinal protozoa. The ability of paromomycin to inhibit C. parvum infection of a differentiated human enterocyte cell line was evaluated in vitro. Paromomycin concentrations ranging from 50 to 5000 micrograms/ml inhibited infection at 24 h in a dose-dependent fashion. Concentrations greater than 1000 micrograms/ml, which are theoretically achievable in the bowel lumen, inhibited infection by greater than 85% (P less than .001). Prospective clinical trials of paromomycin for the treatment of cryptosporidiosis in patients with AIDS are warranted.
Marshall
R J
RJ
Case Western Reserve School of Medicine, Cleveland, Ohio.
Flanigan
T P
TP
D000818:Animals; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D016785:Cryptosporidium parvum / Q000187:drug effects*; D006801:Humans; D007422:Intestines / Q000166:cytology / Q000469:parasitology*; D010303:Paromomycin / Q000494:pharmacology*
D010303:Paromomycin